Mass Spectrometry-Based Metabolomics Diagnostics: Promises, Current Developments and Pitfalls

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 882

Special Issue Editors


E-Mail Website
Guest Editor
Department of Analytical Chemistry, Faculty of Sciences, University of Granada, Av. Fuentenueva s/n, E−18071 Granada, Spain
Interests: metabolomics; metabolic disease; endocrine disease; analytical chemistry

E-Mail Website
Guest Editor
Core Facility Metabolomics, Research Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, 18196 Dummerstorf, Germany
Interests: regulation of lipid metabolism; lipidomics; metabolomics; mass spectrometry and analytics (GC-MS/MS, MALDI-TOF MS, TLC, HR-ESI-MS/MS)
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, MS-based metabolomics has emerged as a promising tool for diagnostics purposes, but despite its promise, no diagnostic tests based on metabolomics have been approved or introduced into the clinic so far. However, there have been more than 2,000 scientific papers published in the past two decades that have used metabolomics analysis for human disease diagnostics, and some of them are good candidates to be introduced in clinical practice in the near future.

This Special Issue is devoted to the most recent advances in metabolomics for diagnostics purposes. We are looking for state-of-the-art research on the subject, able to highlight the potentiality and the limits of such techniques in the early revelation of diseases. Several promises are associated with MS-based metabolomics, such as the early detection of biomarkers, early diagnostics as well as a deeper understanding of the mode of action and the actual status of the disease. On the other end, there are still several challenges associated with MS-based metabolomics, including de novo metabolite identification, differentiation of metabolites from environmental contamination, chromatographic separation of isomers, etc. Furthermore, the statistical validation of the biomarkers is a difficult task, due to the inner variability of the metabolites due to the normal metabolic fluctuations and noisy data.

Dr. Luca Narduzzi
Dr. Beate Fuchs
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mass spectrometry
  • metabolomics
  • clinical test
  • diseases diagnostics
  • metabolic disorders
  • biomarkers

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop